HOUSE_OVERSIGHT_025889.jpg
1.75 MB
Extraction Summary
3
People
8
Organizations
1
Locations
1
Events
3
Relationships
2
Quotes
Document Information
Type:
Article excerpt / webpage printout
File Size:
1.75 MB
Summary
This document discusses the approval, benefits, and high cost of a new cholesterol-lowering drug called Praluent, noting its potential expense concerns raised by CVS Caremark executive Troy Brennan. It details the FDA's approval criteria, focusing on patients with genetic conditions or previous heart disease, and mentions the pricing strategy by Regeneron and Sanofi amidst competition from Amgen. The bottom half of the page lists "Recommended by Forbes" article links.
People (3)
| Name | Role | Context |
|---|---|---|
| Nissen | ||
| Troy Brennan | ||
| Donald Trump |
Organizations (8)
| Name | Type | Context |
|---|---|---|
| Cleveland Clinic | ||
| CVS Caremark | ||
| Amgen | ||
| FDA | ||
| Regeneron | ||
| Sanofi | ||
| Forbes | ||
Timeline (1 events)
FDA clearing Praluent
Locations (1)
| Location | Context |
|---|---|
Relationships (3)
→
→
→
→
→
→
Full Extracted Text
Complete text extracted from the document (1,909 characters)
Nissen, chairman of cardiology at the Cleveland Clinic. “It’s very promising.”
But it will also be very expensive, say Troy Brennan, the chief medical officer of CVS Caremark, the giant
pharmacy benefits manager. “If these drugs are used as broadly as they could be used, they are going to be by far
the most expensive drug class,” Brennan says.
Praluent, an injection, lowers low-density lipoprotein, the so-called “bad cholesterol”, by as much as 60%, far
more than the statin drugs alone. It is the first drug to work by targeting a protein called PCSK9. Mutations in
the gene that makes it can result in patients having lower cholesterol and a dramatically lower lifetime risk of
heart attacks. A rival medicine from Amgen is also expected to be approved soon. The FDA is clearing Praluent
for patients with heterozygous familial hypercholesterolemia, a genetic condition that causes high cholesterol,
and for people who have heart disease, like those who’ve had heart attacks or strokes, who are already taking
the maximum dose of a statin they can tolerate.
Regeneron and its marketing partner Sanofi say Praluent will have a wholesale cost of $40 a day, or $14,600 a
year, for either of two doses, 75 milligrams or 150 mgs. It’s likely that insurance companies will get a
significant discount, because Amgen and Regeneron will compete by giving the insurers rebates.
Recommended by Forbes
But it will also be very expensive, say Troy Brennan, the chief medical officer of CVS Caremark, the giant
pharmacy benefits manager. “If these drugs are used as broadly as they could be used, they are going to be by far
the most expensive drug class,” Brennan says.
Praluent, an injection, lowers low-density lipoprotein, the so-called “bad cholesterol”, by as much as 60%, far
more than the statin drugs alone. It is the first drug to work by targeting a protein called PCSK9. Mutations in
the gene that makes it can result in patients having lower cholesterol and a dramatically lower lifetime risk of
heart attacks. A rival medicine from Amgen is also expected to be approved soon. The FDA is clearing Praluent
for patients with heterozygous familial hypercholesterolemia, a genetic condition that causes high cholesterol,
and for people who have heart disease, like those who’ve had heart attacks or strokes, who are already taking
the maximum dose of a statin they can tolerate.
Regeneron and its marketing partner Sanofi say Praluent will have a wholesale cost of $40 a day, or $14,600 a
year, for either of two doses, 75 milligrams or 150 mgs. It’s likely that insurance companies will get a
significant discount, because Amgen and Regeneron will compete by giving the insurers rebates.
Recommended by Forbes
Most Popular
Photos: America's New Manufacturing Boomtowns
Photos: America's New Manufacturing Boomtowns
Most Popular
Barrel Rolling With A Thrillionaire Entrepreneur
Barrel Rolling With A Thrillionaire Entrepreneur
Most Popular
Photos: The 10 Best And Worst States To Make A Living In 2015
Photos: The 10 Best And Worst States To Make A Living In 2015
Trending on LinkedIn
Donald Trump And The Decline Of American Character--A Cautionary Tale
Donald Trump And The Decline Of American Character--A Cautionary Tale
Most Popular
Photos: America's New Manufacturing Boomtowns
Photos: America's New Manufacturing Boomtowns
Most Popular
Barrel Rolling With A Thrillionaire Entrepreneur
Barrel Rolling With A Thrillionaire Entrepreneur
Most Popular
Photos: The 10 Best And Worst States To Make A Living In 2015
Photos: The 10 Best And Worst States To Make A Living In 2015
HOUSE_OVERSIGHT_025889
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document